Pharvaris publishes review on bradykinin B2 receptor as therapy target
Go back to Pharvaris publishes review on bradykinin B2 receptor as therapy target| (NASDAQ: PHVS) | Delayed: 36.37 -1.63 (4.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $38.00 | 52 Week High | $ | |||
| Open | $38.09 | 52 Week Low | $ | |||
| Day High | $38.20 | P/E | N/A | |||
| Day Low | $36.08 | EPS | $ | |||
| Volume | 579,808 | |||||
